Overview

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-11-30

Target enrollment:

Participant gender:

Summary

The aim of the study is to compare the efficacy and safety of two JY09 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)

Phase:

PHASE3

Details

Lead Sponsor:

Beijing Dongfang Biotech Co., Ltd.

Treatments:

dulaglutide
Metformin